Addex Therapeutics LtdADXNNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank59
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P59
Within normal range
vs 2Y Ago
0.3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 24.48% |
| Q2 2025 | 110.21% |
| Q1 2025 | 623.09% |
| Q4 2024 | -108.00% |
| Q3 2024 | -57.80% |
| Q2 2024 | 2.99% |
| Q1 2024 | -60.57% |
| Q4 2023 | 7.87% |
| Q3 2023 | 83.78% |
| Q2 2023 | 14.64% |
| Q1 2023 | -96.52% |
| Q4 2022 | 230.51% |
| Q3 2022 | -62.85% |
| Q2 2022 | 86.56% |
| Q1 2022 | -28.33% |
| Q4 2021 | 93.77% |
| Q3 2021 | -51.62% |
| Q2 2021 | 35.80% |
| Q1 2021 | -45.72% |
| Q4 2020 | 155.82% |
| Q3 2020 | -14.66% |
| Q2 2020 | -34.72% |
| Q1 2020 | -39.43% |
| Q4 2019 | 170.43% |
| Q3 2019 | -36.41% |
| Q2 2019 | 89.50% |
| Q1 2019 | 26.99% |
| Q4 2018 | -0.00% |
| Q3 2018 | 36.04% |
| Q2 2018 | 0.00% |
| Q1 2018 | 40.70% |
| Q4 2017 | 0.00% |
| Q3 2017 | 29.03% |
| Q2 2017 | 0.00% |
| Q1 2017 | -18.06% |
| Q4 2016 | 0.00% |
| Q3 2016 | 32.09% |
| Q2 2016 | 0.00% |
| Q1 2016 | 27.69% |
| Q4 2015 | 0.00% |